Earnings call transcript: Abbott Labs Q1 2026 results align with expectations

Abbott Labs reported Q1 2026 adjusted EPS of $1.15, matching consensus, on revenue of $11.16 billion versus $11.0 billion expected, but shares fell 4.69% pre-market on concerns tied to Exact Sciences integration and a weaker respiratory season. The company raised clarity on guidance, with Q2 EPS of $1.25-$1.31 and FY 2026 comparable sales growth of 6.5%-7.5%, while absorbing a $0.20 EPS dilution from Exact Sciences. Management also flagged a rebound in CGM growth, continued China VBP recovery, and stable dividend support, but near-term execution risks remain.

Analysis

The market is pricing ABT as if this is a clean miss, but the real issue is timing mismatch: the earnings print was fine, yet the guidance reset exposed how much of 2026 is being asked to absorb acquisition dilution, respiratory normalization, and uneven diagnostics cadence all at once. That creates a near-term multiple overhang because investors will anchor on the lowered EPS path, not the long-duration revenue optionality from Exact Sciences and CGM. In other words, this is less about fundamental deterioration than about the street having to re-rate a more complex earnings bridge.

The second-order effect is that ABT is quietly becoming a cleaner “portfolio quality” trade: pharma and medtech are doing the heavy lifting while diagnostics and nutrition are the recovery legs. That usually helps once confidence returns, because the downside becomes more self-contained than the headline diversified model suggests. But it also means the stock will likely remain hostage to execution credibility in the next 1-2 quarters; any slippage in core lab or CGM would force investors to question whether the growth reacceleration thesis is real or just pushed out.

Competitive dynamics look favorable for EXAS and for large-cap diabetes/medtech peers if ABT’s integration consumes management bandwidth, but that pressure should be temporary. The bigger contrarian point is that the pre-market drawdown may be overdone if you believe the company’s own sequencing: Q2 should show cleaner CGM comping, FX tailwind remains a modest help, and the Exact Sciences asset should contribute more visibly once the market stops treating it as dilution-only. The setup is a classic multiple compression / earnings durability mismatch, and those tend to mean-revert over months, not days.

Key Decisions for Investors

• Long ABT on a 4-8 week horizon after the pre-market selloff; risk/reward favors a rebound if Q2 commentary confirms CGM reacceleration and diagnostics stabilization. Use a stop below the recent 52-week-low zone to limit downside if integration concerns worsen.
• Pair trade: long ABT / short a lower-quality diagnostics or elective medtech basket over 1-3 months. The thesis is that ABT’s diversified cash flows and dividend support should outperform once the market rotates away from pure EPS dilution headlines.
• Sell ABT downside puts or structure a bullish put spread into the next earnings cycle; implied volatility should remain elevated while the market digests the new guidance, but the business mix reduces crash risk versus a single-product story.
• If you want cleaner exposure to the integration story, consider a relative long EXAS vs short a medtech name with no acquisition catalyst. EXAS benefits from being re-underwritten inside a larger-cap platform, while peers without catalysts may lag as capital reallocates.
• Avoid chasing strength in pure diabetes competitors until ABT’s Q2 CGM print confirms the rebound; if Libre growth re-accelerates, it likely caps near-term upside in names relying on CGM share gains.